TSE:4506Pharmaceuticals
Why Sumitomo Pharma (TSE:4506) Is Up 6.1% After Strong Q1 Earnings And Cell Therapy Progress
Sumitomo Pharma Co., Ltd. reported first-quarter 2026 results with sales of ¥129,495 million and net income of ¥16,997 million, both higher than a year earlier, alongside basic earnings per share from continuing operations of ¥39.02.
Separately, Sumitomo Pharma America, Inc. advanced its regenerative medicine efforts as the first patient received DSP-3077 iPS cell-derived retinal sheet implantation in an early-stage trial for non-syndromic retinitis pigmentosa, underlining the group’s push...